Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Weight Management in Bangladesh
NCT06918405Phase 3Active, not recruiting
- Sponsor
- Chattogram Medical College
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tirzepatide in obesity and Overweight, sponsored by Chattogram Medical College. Primary endpoint: Change in body weight at 52 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06918405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918405.